Abbvie (ABBV) is in discussions to acquire mental health therapeutics company Gilgamesh Pharmaceuticals, with a potential deal potentially valuing Gilgamesh at roughly $1B, Bloomberg’s Eyk Henning, Madison Muller, and Liana Baker report, citing people familiar with the matter. Talks are ongoing and could still be delayed or even fall apart, the authors note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Notable companies reporting before tomorrow’s open
- AbbVie’s Ubrogepant Study: A Potential Game-Changer for Menstrual Migraine
- AbbVie Advances Lutikizumab Study for Hidradenitis Suppurativa
- AbbVie’s Promising Study on Mirvetuximab Soravtansine for Platinum-Resistant Cancers
- AbbVie’s Promising NSCLC Study: A Potential Game-Changer for Cancer Treatment